Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe

被引：59

作者：

Urbano-Ispizua, A

Schmitz, N

de Witte, T

Frassoni, F

Rosti, G

Schrezenmeier, H

Gluckman, E

Friedrich, W

Cordonnier, C

Socie, G

Tyndall, A

Niethammer, D

Ljungman, P

Gratwohl, A

Apperley, J

Niederwieser, D

Bacigalupo, A

机构：

[1] Osped San Mariano, Dept Haematol, I-16132 Genoa, Italy

[2] Hosp Clin Barcelona, Dept Hematol, E-08036 Barcelona, Spain

[3] Allgemein Krankenhaus St Georg, Dept Hematol, Hamburg, Germany

[4] Univ Nijmegen, Med Ctr St Radboud, Dept Hematol, NL-6526 ED Nijmegen, Netherlands

[5] Osped Civile, Dept Oncohematol, Ravenna, Italy

[6] Free Univ Berlin, Klinikum Benjamin Franklin, Dept Hematol, D-12200 Berlin, Germany

[7] Hop St Louis, BMT Unit, Dept Hematol, F-75475 Paris, France

[8] Univ Ulm, Abt Pediat 2, D-89069 Ulm, Germany

[9] Hop Henri Mondor, Dept Hematol, F-94010 Creteil, France

[10] Univ Basel, Felix Platter Spital, Reumatol Klin, CH-4056 Basel, Switzerland

[11] Univ Tubingen Hosp, Dept Pediat, Tubingen, Germany

[12] Huddinge Univ Hosp, Dept Hematol, S-14186 Huddinge, Sweden

[13] Kantonsspital, Dept Hematol, CH-4031 Basel, Switzerland

[14] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Haematol, London SW7 2BZ, England

[15] Univ Leipzig, Div Internal Med 2, Leipzig, Germany

来源：

BONE MARROW TRANSPLANTATION | 2002年 / 29卷 / 08期

关键词：

haemopoietic transplantation; indications; recommendations; practice; Europe;

D O I：

10.1038/sj.bmt.1703535

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The Accreditation Sub-Committee of the EBMT regularly publishes special reports on current practice of haemopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders. Major changes have occurred since the last report in 1998. Haemopoietic stem cell transplantation today includes allogeneic and autologous stem cells derived from bone marrow, peripheral blood and cord blood. With reduced intensity conditioning regimens in allogeneic transplantation, the age limit has increased, permitting the inclusion of older patients. New indications have emerged, such as autoimmune disorders and AL amyloidosis for autologous, and solid tumours for allogeneic transplants. Other indications, such as autologous transplantation for breast cancer have been challenged. An updated report with revised tables and operating definitions is presented here.

引用

页码：639 / 646

页数：8

共 5 条

[1] Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998 [J].